Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.

Clémenson C, Chargari C, Liu W, Mondini M, Ferté C, Burbridge MF, Cattan V, Jacquet-Bescond A, Deutsch E.

Mol Cancer Ther. 2017 Oct;16(10):2107-2119. doi: 10.1158/1535-7163.MCT-17-0112. Epub 2017 Jun 15.

2.

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.

Guffanti F, Chilà R, Bello E, Zucchetti M, Zangarini M, Ceriani L, Ferrari M, Lupi M, Jacquet-Bescond A, Burbridge MF, Pierrat MJ, Damia G.

Neoplasia. 2017 Jan;19(1):35-42. doi: 10.1016/j.neo.2016.11.008. Epub 2016 Dec 15.

3.

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.

Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.

4.

Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009;2(102):er11.

PMID:
20039471
5.

Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009 Dec 8;2(100):ra80. doi: 10.1126/scisignal.2000643. Erratum in: Sci Signal. 2009 Dec 22;2(102):er11. Corrected and republished in: Sci Signal. 2009;2(102):er11.

6.

Three-dimensional in vitro anglogenesis in the rat aortic ring model.

West DC, Burbridge MF.

Methods Mol Biol. 2009;467:189-210.

PMID:
19301672
7.

The effect of extracellular pH on angiogenesis in vitro.

Burbridge MF, West DC, Atassi G, Tucker GC.

Angiogenesis. 1999;3(3):281-8.

PMID:
14517427
8.

The role of the matrix metalloproteinases during in vitro vessel formation.

Burbridge MF, Cogé F, Galizzi JP, Boutin JA, West DC, Tucker GC.

Angiogenesis. 2002;5(3):215-26.

PMID:
12831062
9.

Decrease in survival threshold of quiescent colon carcinoma cells in the presence of a small molecule integrin antagonist.

Burbridge MF, Venot V, Casara PJ, Perron-Sierra F, Hickman JA, Tucker GC.

Mol Pharmacol. 2003 Jun;63(6):1281-8.

PMID:
12761337
10.

Improved quantification of angiogenesis in the rat aortic ring assay.

Blacher S, Devy L, Burbridge MF, Roland G, Tucker G, Noël A, Foidart JM.

Angiogenesis. 2001;4(2):133-42.

11.

Rat Aortic Ring : 3D Model of Angiogenesis In Vitro.

Burbridge MF, West DC.

Methods Mol Med. 2001;46:185-204. doi: 10.1385/1-59259-143-4:185.

PMID:
21340920
12.

Angiogenesis assays using chick chorioallantoic membrane.

West DC, Thompson WD, Sells PG, Burbridge MF.

Methods Mol Med. 2001;46:107-29. doi: 10.1385/1-59259-143-4:107.

PMID:
21340916
13.
14.

Experimental antitumour activity of S 16020-2 in a panel of human tumours.

Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierré A, Atassi G.

Eur J Cancer. 1997 Oct;33(11):1881-7.

PMID:
9470851

Supplemental Content

Loading ...
Support Center